* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Pharmaceuticals and the Elderly - WHO archives
Survey
Document related concepts
Orphan drug wikipedia , lookup
Drug discovery wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Drug interaction wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmaceutical marketing wikipedia , lookup
Electronic prescribing wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Transcript
Chapter 7.2: Cross-Cutting Issues: Elderly Priority Medicines for Europe and the World "A Public Health Approach to Innovation" Background Paper Pharmaceuticals and the Elderly By Marjolein Willemen, Dr. P.A.F. Jansen and Prof. Dr. H.G.M. Leufkens 7 October 2004 7.2-1 Chapter 7.2: Cross-Cutting Issues: Elderly Table of Contents Summary................................................................................................................................................ 3 Introduction........................................................................................................................................... 3 Size and Nature of Disease Burden ................................................................................................... 4 Epidemiological Trends................................................................................................................... 4 What are the Current or Likely Future Factors that Impact on Disease Burden at the Following Levels, and in What Way Why: ................................................................................... 8 Individual, Community, Household .................................................................................... 9 Health Care Sector ................................................................................................................. 13 Non-Health Factors ............................................................................................................... 13 Control Strategy .................................................................................................................................. 13 Individual Problems....................................................................................................................... 13 General Problems ........................................................................................................................... 14 How effective is it, or could it be? ................................................................................................ 14 Why Does the Disease Burden Persist? ........................................................................................... 15 Past/Current Research into Pharmaceutical Interventions ........................................................... 16 Current "Pipeline" of Products ......................................................................................................... 17 Opportunities for Research into New Pharmaceutical Interventions ......................................... 17 Conclusion ........................................................................................................................................... 20 References ............................................................................................................................................ 20 7.2-2 Chapter 7.2: Cross-Cutting Issues: Elderly Summary The number of elderly is increasing over the world. It is estimated that by the year 2020 the proportion of people aged 60 and over will be 25% worldwide. The ageing process in Europe is even at a higher level.1, 2 The ageing of the society comes along with several specific problems. The increased frailty of the elderly, the increasing prevalence of diseases (including co-morbidities) and the large numbers of drugs used per patient have a major impact on the health systems.3, 4 The rate of adverse drug reactions in elderly is higher than in other parts of the society, 5 whereas about between 27.6 and 51% of the adverse drug reactions in elderly are preventable.5-7 The altered body-functions in older persons (e.g. changing body-composition, renal function and liver metabolism) may require adapted dosages.3, 8 Under- and overuse are also important problems that occur frequently among the elderly. Underuse is often not a well-recognised problem, but it may lead to unnecessary loss of health. Underuse is caused by several reasons, ranging from poor access to health care to practical problems with formulations (e.g. difficulties with opening medication containers). On the other hand polypharmacy is a well-recognised problem in the elderly. Numerous studies have shown that elderly patients often continue using – sometimes obsolete - drugs without indication.9 To improve optimal pharmacotherapy and to provide the best possible care, there is a special need in developing adapted formulations for medications specially used by the elderly and pharmaceutical care programs for elderly.10-12 In the last decade, the awareness of the impact of the growing numbers of elderly has increased. The ageing society has been one of the Key Actions of the 5th Framework Program of the European Union. Within this program, much attention is paid to effective and efficient delivery of health and social care services to older people.13 Despite the efforts made by the 5th FP, it is important to improve the knowledge of drug effects in the elderly by including them in clinical trials. There is a need for special guidelines which stimulate the inclusion of the people aged 70 and older in clinical trials.4 As stated in the 5th FP, basic research is necessary to enhance the quality of life of the elderly, and to keep them independent as long as possible, thereby reducing the burden on the public health systems. If the underlying processes of ageing and of the age-depended disorders are known, it will be easier to develop therapies and to keep the elderly as healthy as possible.8 Introduction In his key-note address to the International Society for Pharmacoepidemiology and Risk Management in August 2003, Robert Califf from Duke University talked about the elderly patient using a plethora of drugs, having multiple morbidities and suffering from renal or hepatic failure as a Bermuda Triangle: 'you can get in, but......you 7.2-3 Chapter 7.2: Cross-Cutting Issues: Elderly never get out'.14 We can derive an important message from this quote. The number of elderly people is rising dramatically and is expected to continue rising even more in the next couple of decades.1 The boom in the ageing population will increase the demand for efficacious, safe and affordable medicines enormously.15 Although most medications are prescribed to and used by patients aged over 60 years old, this does not imply that innovation in pharmacological knowledge related to drug usage in the elderly has been developed proportionally. The age-related problems were high on the agenda of the 5th Framework Programme (FP) of the European Union (1999-2002). The aim of the 5th FP to sponsor research in the areas that are related to the ageing of the society, both on individual (e.g. agerelated illnesses) and society (e.g. health and social care services) level. In the period 1999-2002 the European Union provided a total funding of €190,1 million for all projects and actions considering the age-related disorders.13 The proportion of the population aged 60 and over, is growing each year. By the year 2025, the world will host 1.2 billion people aged 60 and over; rising to 1.9 billion older people in 2050.1 People are living longer in relatively healthy condition and with less disability. The ageing of the population will have a great impact on the size, organisation, strategy and economics of national health systems, since demands will increase, will change frequently over time, and consumers will dictate more then ever in the health care arena. 15 An ageing population is likely to lead to an increase in demand for medical technologies, care facilities, physically impaired and disability support services, and tailored forms of housing and other physical surroundings.15 Although there are diseases that occur more frequently in and are typical for the elderly (e.g. cardiovascular diseases, dementia/Alzheimer's disease, diabetes, Parkinson's disease, COPD, depression and musculoskeletal disorders) the use of medicines in the elderly as a more general, 'cross-cutting' issue requires careful attention and analysis. Virtually all-demanding topics in the pharmaceutical marketplace (e.g. cost containment, patient safety, risk/benefit balance, prioritising of health needs, long-term outcomes of the use of medical technologies) show up in relation to the frail section of our societies but with extreme amplification. Moreover drug use in the elderly has a number of specifically relevant features as well. 16, 17 Size and Nature of Disease Burden Epidemiological Trends Ageing People aged 60 and older are a growing part of both western and global communities (see Figure 7.2.1). In 2000, about 20% of the population worldwide was aged 60 and over. By the year 2020, this proportion of people aged 60 years and over will be 25%. In Europe, this process of ageing is more pronounced. By the year 2020, forecasts say that the percentage of people aged 60 and over will be about 50%.1, 2 Interestingly, while the overall trend is 7.2-4 Chapter 7.2: Cross-Cutting Issues: Elderly virtually similar in all countries, there is considerable variation between individual countries, and between Europe and the rest of the world with respect to the slope and speed of these developments.2 Figure 7.2.1: Population distribution: recent history and next decades (Data from World Population Prospects, The 2002 revision database, UN Population division)2 World Europe 40 35 35 30 30 2000 2005 2010 2015 2020 20 15 % of total population % of total population 25 25 2000 2005 2010 2015 2020 20 15 10 10 5 5 0 0 0-4 5-14 15-24 25-59 60-64 65-79 80 + 0-4 Age groups 5-14 15-24 25-59 60-64 65-79 80+ Age groups Diseases which Occur More Frequent Among the Elderly This section discusses the nature of the disease burden of a number of geriatric diseases in more detail. The sample presented is not intended to be complete but the purpose is to give an impression of the most relevant topics related to geriatric medicine and possible implications for pharmacotherapy in the elderly (Table 7.2.1). Table 7.2.1: Summary of the burden of some geriatric diseases Cardiovascular diseases Surge in hospital admissions High mortality Disability Polypharmacy Dementia (incl. Alzheimer's disease) High societal burden Co-morbidities Great demands health systems High costs Parkinson's disease COPD Depression Musculoskeletal disorders Unknown aetiology High burden Underdiagnosed Hospital admissions Drug-induced parkinsonism Threat to quality of life Hospital admissions High mortality Disability High burden Disability Comorbidities High costs High costs Drug-induced osteoporosis High costs Comorbidities Cardiovascular Diseases (Hypertension, Heart Failure) The prevalence of cardiovascular diseases increases dramatically with age.18 The prevalence of hypertension in the elderly (mean age 80 years) is estimated around 60%. Hypertension is 7.2-5 Chapter 7.2: Cross-Cutting Issues: Elderly an important risk factor for the occurrence of other cardiovascular disorders such as myocardial infarction and stroke.19, 20 In many western societies, an epidemic of heart failure has emerged. This is partly a result of the ageing population, but also because of the success in applying modern technologies to treat patients immediately after they have suffered a myocardial infarction. Nowadays, the prevalence of heart failure is about 3% in people aged 45-64 and increases up to 10% in people aged >75 years.21 Heart failure is one of the leading causes of hospital admissions in the elderly, also being responsible for high mortality rates, disabilities and costs.22 Pharmacological prevention of cardiovascular diseases deals essentially with lowering blood pressure, the cholesterol-lipid balance and/or antithrombotic medicines, three strategies from which the very elderly (85 years and older) are often excluded because of lack of evidence in this age group.23 These preventive strategies need to be addressed, if indicated, already in people's 40's or 50's of age.23 Moreover, pharmacological treatment of heart failure can be improved. Patients with decreased left ventricular function and manifest heart failure often do not receive drugs with proven effects on morbidity and mortality (such as ACE-inhibitors and beta-blockers).22 Dementia (Including Alzheimer's Disease) Dementia is a term that covers different forms of neurological diseases. It includes Alzheimer's disease, but also vascular dementia, dementia with Lewy bodies, front temporal dementia and dementia secondary to another disease process (e.g. stroke). 24 In Europe and North America, Alzheimer's disease is seen to be the more prevalent than vascular dementia. The overall prevalence of dementia in the elderly is 5-10%.24 It is estimated that the prevalence increases exponentially with age: the established prevalence of dementia doubles every five years (in people aged 65 and older), up to a prevalence of 30 to 40% in people aged between 90 and 95.25, 26 Dementia is at the top of virtually every assessment of burden of disease in the very old, mainly because of the large number affected by the disease and the relative young age at onset of the disease. Unless the pharmaceutical industry spends an enormous amount of money in research on dementia, the aetiology of dementia is still unknown. The existing therapies do not stop or reverse the illness, only delay the onset and provides symptomatic relief for a short period of time (six to eighteen months) People with diagnosed dementia may continue to live for 20 years or longer thereby suffering from severe disabilities and having a great need for comprehensive care and support. Dementia weighs heavily to the societal disease burden because it relatively affects most family or other directly involved communities.27, 28 Parkinson's Disease (PD) Although basic research is adding tremendously to a better understanding of Parkinson’s disease, it’s aetiology is still unknown. Because of the increasing numbers of people affected with PD, it is important to continue investing in unravelling the underlying processes of the disease, as this strategy is most likely the most successful one finding appropriate therapy.29 Before the age of 60, the incidence rates of PD are low, but increase in people aged 60 years and over.29 A study by Twelves, who reviewed several incidence studies on PD, shows that the incidence in the age group 50-59 years ranges between 16 and 20/100,000/year. These rates increase in the age group 60-69 up to 30-90/100,000/year. In people aged between 70-79, the incidence rates increases up to 60 and 200/100,000/year.29, 30 Although in terms of aetiology a different disease, drug-induced parkinsonism should be mentioned as well in 7.2-6 Chapter 7.2: Cross-Cutting Issues: Elderly this section. Many of the drugs which can induce parkinsonism are commonly used by elderly patients (e.g. antidepressants, antipsychotics).31 COPD Chronic Obstructive Pulmonary Diseases (COPD) is a very common disease, but is essentially preventable - up to 80% of COPD is attributable to smoking - and affects dramatically the quality of life and life expectancy.32 Moreover, the disease is costly because of heavy burden on the health care system, heavy demands for health care, and worsening of quality of life.33 The prevalence increases rapidly with age, especially in smokers. Because of the progressive nature of the disease, diagnosis is often late, and at a moment when preventive strategies are virtually meaningless.32 There are no pharmacological therapies available that reduce or reverse the loss of lung function. The prevalence of COPD in people aged 4059 years is about 1% and this number increases up to 13-23% in people aged 65-84 years old.34 Patients with COPD show frequently concurrent diseases suffering from heart failure. This pattern of co-occurrence of two severe diseases in the elderly represents a major and typical category of geriatric morbidity, frequently also leading to a cascade and clustering of other diseases (e.g. co-occurrence of pneumonia, steroid induced osteoporosis, hip fractures and the like).35 It is of great importance to pay attention to smoking cessation programs in patients of younger age top to prevent them from developing COPD. Depression There is still a poor understanding of the underlying mechanisms of mental disorders. This leads to difficulties in developing effective and safe medicines, but also to underdiagnosis and undertreatment of the disorder in the elderly. The treatment is important because depression is associated with other morbidities (e.g. more difficult recovering after myocardial infarction, greater risk to fall).18 For a long time the seriousness (in terms of prevalence, effects on quality of life and societal costs) of this disorder in the elderly was not well recognized and understood. The prevalence of depression varies in different studies; dependent on whether the clinical condition or the symptomatology is studied. 36 In the community, the prevalence of elderly people with depressive symptoms is estimated to be around 15%, while the prevalence of a major depressive disorder ranges between 1-3%.37 In the ambulatory setting, the rates are much higher: about 20% of the elderly has depressive symptoms and the prevalence of a major depressive disorder is 10-12%.36 These prevalences are doubled and sometimes tripled in patients with severe somatic morbidities (e.g. cancer) or severe expressions of chronic diseases (e.g. arthritis, diabetes, post-myocardial infarction). Depression as a co-morbidity represents a heavy burden also because affects negatively management of the somatic disease (e.g. non-compliance, etc).18, 37 Musculoskeletal Disorders (MSDs) Diseases affecting the joints and bones (MSDs) are at the top of virtually every listing on disease burden in the elderly, both from the numbers perspective and the implications for quality of life and economic costs.38 The most important MSDs are rheumatoid arthritis, osteoarthritis (OA) and osteoporosis.39 The first one counts because of disease severity, the two other because of numbers. MSDs are associated with high levels of pain and disability. Rheumatoid arthritis, a disease where severe and erratic inflammation is the main concern, is 7.2-7 Chapter 7.2: Cross-Cutting Issues: Elderly relatively rare (<1% of the population).40 OA on the other hand is a common disease of the aged and frail. It is estimated that about 9.6% of men and about 18% of women aged 60 and over, have symptomatic OA.38 The treatment of MSDs is symptomatic; there are no treatments available which can cure the diseases. Osteoporosis has two other important dimensions. Very often the disease is drug induced (e.g. corticosteroids) and is thereby associated with diseases where heavy steroid use is prevalent (e.g. asthma, COPD and rheumatic disorders), and the most important signature of the disease burden is osteoporosis as a risk factor for fracture, particularly the hip.41 The prevalence of osteoporosis increases with age, and women are much more affected than men. The prevalence rises from 5% in women aged 50, up to 50% in women aged 85 years. In men, the prevalence is 2.4% (50 years) up to 20% (85 years).38 What are the Current or Likely Future Factors that Impact on Disease Burden at the Following Levels, and in What Way Why: In the 19th and 20th century, improvements in socio-economic and environmental conditions have contributed significantly to increase of life expectancy in most parts of the western world. These improvements included better hygiene, drinking water and nutrition, better housing and more physical exercise.17 Wealth in general, in combination with improved preventive (e.g. vaccines) and direct medical care, has dramatically increased life expectancy during the last century (see Figure 7.2.2). This factor together with a decrease in fertility (below replacement level in more developed countries, see Figure 7.2.3) is an important driver behind the trend that the proportion of elderly in community is growing steadily. In the next decade, the baby-boom generation (born between 1946 and 1964) will reach the age of 60. This growing proportion of older people will have enormous impact on the whole society, both medically, socially and in terms of economics.2, 17 Figure 7.2.2: Life expectancy over time Figure 7.2.3: Fertility rate over time (Data from World Population Prospects, The 2002 revision database, UN Population division) 2 Life expectancy Fertility rate 90 7 80 6 70 5 World More developed countries Less developed countries Least developed countries 50 40 Fertility rate Age 60 World More developed countries Less developed countries Least developed countries 4 3 30 2 20 1 10 0 0 1950 1960 1970 1980 1990 2000 2010 2020 2030 2040 1980-1985 1990-1995 2000-2005 2010-2015 2020-2025 2030-2035 2040-2045 Year Year 7.2-8 Chapter 7.2: Cross-Cutting Issues: Elderly Individual, Community, Household Among older people the prevalence of almost all diseases increases.3 Therefore, older people are using more health care technologies, care, drugs, etc. than younger people. 4 It is studied that the number of drugs used increases almost linearly with age.42 Several studies in different settings have shown that the elderly use an average of 2-6 prescribed medications and 1-3 non-prescribed medications.43 At least 80% of the people aged 60+ are using one or more drugs on prescription.6, 44, 45 More than 40% of the elderly are using 5 or more drugs each week.4, 6 The process of ageing, the high prevalence of co-morbidity of diseases, the large numbers of drugs used, and complexities related to the use of medicines in this section of the population, cause a plethora of problems. Polypharmacy The term 'polypharmacy' is used in two different meanings. If one speaks about polypharmacy as 'using multiple drugs' it does not appoint polypharmacy as a bad event. Less medication does not necessarily mean better treatment for the patient, and more attention has to be paid to appropriate prescribing instead of less prescribing.42, 46 The treatment and prevention of cardiovascular disease is a good example of appropriate polypharmacy. To obtain optimal pharmacotherapy, the use of several different drugs is required (e.g. antiplatelet therapy, cholesterol-lowering drugs and blood pressure lowering drugs).47 However it is not yet clear what the additional risk reduction is of combining several preventive drugs. For many physicians, appropriate prescribing is not that easy. To obtain optimal prescription, it is necessary that physicians have a good understanding of the pathophysiology of the disease, the changes of pharmacology with increasing age 8 and in the pharmacology of the drugs. Several studies show that inappropriate prescribing occurs frequently among the elderly and that it is often related to polypharmacy.48-50 Despite the advantages of polypharmacy in some specific cases, polypharmacy is not favourable in all cases. If polypharmacy is seen as the 'administration of more medications than are clinically indicated', a negative event which has to be avoided, occurs. It is studied that in the elderly the percentage of medication without indication or a less than optimal indication, ranges between 55 and 59% of the prescriptions.51, 52 This kind of polypharmacy is problematic especially in the elderly because it increases unnecessary the risks of adverse drug reactions, geriatric syndromes (like cognitive impairment and delirium) and the health care costs.9 Many patients are treated by different physicians, who often do not know about the other medication a patient is using, prescribed by other doctors. In most countries, people do not have a regular pharmacist or a family doctor who can review all patients' medication. Moreover, many people do not only use medicines on prescription, but also a large amount of 'over the counter' (OTC) drugs. These OTC-medicines include NSAIDs, antihistamines but also vitamins, minerals and herbals. Most patients do not realize that the OTC-medications they are using can also influence their therapy, for example by interacting with their prescribed medications. Many patients are not aware that OTC-medicines can have similar actions as prescription drugs (e.g. NSAIDs and antihistamines). Because of this ignorance, most patients do not report the use of OTC-medications.45 7.2-9 Chapter 7.2: Cross-Cutting Issues: Elderly Adverse Drug Reactions The risk of adverse drug reactions (ADRs) increases with the number of individual drugs patients are using. Because elderly are using more drugs in comparison with the younger population, it is likely that more adverse drug reactions occur in people aged 65 and over.53 The incidence of ADRs in elderly was found to be about 5%, whereas the incidence of ADRs in non-elderly was about half of this.5 A meta-analysis suggests that adverse drug reactions rank between the fourth and sixth cause of death in hospitalized patients.54 ADRs are responsible for unnecessary hospital admissions, which cause an unnecessary loss of health and an unnecessary waste of money. In several studies, the percentage of hospital admissions due to adverse drugs reactions ranges from 4.1% in young people, up to 16.6% in the elderly.55 It is important to realize that many adverse drug reactions are preventable: the percentage of preventable ADRs in the elderly ranges between 27.6% and 51%. 5-7 Therefore, if it is possible to prevent unnecessary ADRs, it will yield an enormous improvement of health and it will save a large amount of money. In several studies the costs of hospital admissions due to adverse drug reactions have been calculated. The amounts ranges between €182,927 per year (29-bed ward of general medicine)56 to €261,220 per year (23-bed ward of general medicine).57 Therefore, these costs are considerable, certainly at a (inter)national level. Next to the adverse drug reactions, other drug-related problems like drug-drug interactions and contra-indications cause problems in the elderly. These medication errors are also associated with hospital admissions, high burden of disease and considerable costs.58, 59 As with the adverse drug reactions, a large number of these other drug-related problems can be prevented.59 Co-Morbidity The incidence of diseases increases with age. Many elderly have several different disorders at the same time. This re-occurrence of diseases can lead to problems.3, 60 There is too little knowledge of the interference of different diseases, so this will be an important domain for research by industry and academics in the near future. In the case of re-occurrence of several disorders, therapy must also be adapted. For most patients, only the disease with the highest risk on events, or with the greatest impact on life, is treated.60 To structure the care of the elderly, and thereby providing the best care possible, it is necessary that the physicians not only treat one organ (e.g. for mental disorders a psychiatrist and cardiovascular diseases the cardiologist), but one physician (e.g. specialized in geriatrics) who treats the patient as a whole. Altered Body Functions3, 8 In older persons, body functions change. Almost all parts of the body show deterioration in structure and/or function with increasing age. In healthy elderly, this might not be problem, but it may be more difficult or take more time for an elderly person to recover from illness. It is also more likely for elderly to be left with permanent disability after illness. Changes in pharmacokinetics and pharmacodynamics can influence the metabolism and/or excretion of 7.2-10 Chapter 7.2: Cross-Cutting Issues: Elderly medicines. Prescribers must be aware of the risk of altered body functions, because it may cause unexpectedly higher or lower drug levels. This can result in preventable adverse drug reactions, and, on the other side, in little or no effect of therapy. Change in Body Composition3 With advancing age, the body composition alters. Because of a reduction in body water and lean body mass, body fat relatively increases. This can induce a different partition of a drug in the body. Polar drugs will have decreased distribution volumes, which result in higher serum levels. Non-polar drugs will have increased partition volumes, thereby resulting in prolonged half-lives. This can be important to know to obtain an accurate dosage and dosage regime, especially in drugs with a narrow therapeutic range. Changes in (Liver) Metabolism3, 8 Many drugs are metabolised in liver (first-pass metabolism), either to be excreted more easily or to be activated (pro-drugs). In elderly people, there is a reduced blood flow to the liver and the mass of the liver decreases. This implicates that first-pass metabolism results in higher bioavailability for drugs that are metabolised for excretion. On the other hand, the bioavailability of pro-drugs will be decreased. Changes in Renal Function8 In the elderly, a reduction of renal function is common. This kind of reduction decreases the clearance of mainly water-soluble drugs and glucuronised metabolites. Whether or not this might be a problem, is dependent on the toxicity and therapeutic range of the drug.8 Underuse of Medication Underuse of medication in the elderly is an under-estimated problem, but it occurs frequently among elder patients. As described above, overuse (polypharmacy) receives much attention from policy makers, while it is not unfavourable in all cases (e.g. cardiovascular diseases). Underuse is also a problem among the elderly, but policy makers are not familiar with it.4 It is important to realize underuse can cause harm to patients and therefore results in high costs. Underuse of medication can be explained in several ways. Many older people and their family hesitate to contact a physician. Many health problems are signs of ageing, and people think they just have to accept these problems. This is not true in all cases, because nowadays there is a wide range of therapies and medications available. Many of these medications are effective and have little adverse effects, but, as described above, not for all disorders effective and safe treatments are available. Not only do patients hesitate to ask for therapies and/or medication, underuse can also be caused by underprescription by physicians. In the past, "the less medications the better" was a common opinion. In the last few years, this opinion is changing. Less medication is not the main pursuit. More important is appropriate prescribing. In this point of view, early intervention can prevent more serious illness, which is likely, especially in the elderly, who recover less easily from illness than younger people.46, 61 Underuse due to underprescription by physicians can be caused by the tendency of physicians to treat first the disease with highest burden, and the disease with less impact on the patients well-being is pushed into the background.60 Economic barriers can also cause underuse. In many countries, seniors 7.2-11 Chapter 7.2: Cross-Cutting Issues: Elderly with low incomes have little or no access to health care in general or insurance for medications.45 Many elderly do not have enough income to pay for their medications. Because of that, people decide not to use the medications which they are prescribed.4, 45 Another reason for underuse is poor adherence to medication regimes.4, 45 Elderly are in general not less adherent than younger patients. However elderly with depression and/or cognitive problems (like dementia) are likely to have poorer adherence. This will be especially important if there is also a lack of social support. Because of extensive ageing, the numbers of elderly living alone is increasing also. People living together help each other remember important things like taking medication. Therefore, living alone is a risk factor for non-adherence.62 Even uncomplicated problems with formulations such as difficulties to break scored tablets, hamper adherence to the drug-regimen and can make taking medications a discomforting experience for patients. It is expected this interferes with adherence and causes noncompliance.10 It is therefore needed to stimulate the pharmaceutical industry to develop special formulations for the elderly. Underuse is mainly seen with medication for primary prevention (e.g. hypercholesterolemia, hypertension), because patients do not directly benefit.4 To help patients adhere to their medications, it is important that physicians and pharmacists explain the need for the use of medications, and possible drug related problems (like side effects); all adapted to the patient's intellectual capacity.61 It is important to diminish the underuse of medications because it can lead to serious adverse consequences, which will raise the overall costs of medical care.4, 45 Drug Formulations Specifically tailored formulations for medications explicitly used in the elderly are rare. There is a special need for these formulations, because dosage used in the elderly can be different from dosage in younger populations. Special formulations are also needed because of practical problems. Mainly due to poor vision of many elderly but also because of impaired physical and cognitive function,63 problems with opening pill boxes occur frequently among the elderly. 11, 12 Other problems with formulations include too large pills to swallow; difficulties in reading drug monographs or pills which need to be broken.45 Unequal breaking of scored tablets can be problematic, especially when drugs have a narrow therapeutic range.10 The pharmaceutical industry does not pay much attention to this problem, but it is likely that adapted formulations will increase the sale of their medications: elderly are a growing part of society, and they use a great amount of medications. Problems with formulations can cause a discomforting experience for patients, and therefore interfere with adherence and causes non-compliance.10-12 7.2-12 Chapter 7.2: Cross-Cutting Issues: Elderly Health Care Sector Ageing is followed by an increase of frailty and an increase in the use of medical facilities. The increasing number of elderly will have major impact on the health systems. To avoid an excessive impact of the elderly on the health systems, resulting in unacceptable high costs for society, policy makers should realize that planning and evidence-based policy decisions are the only way to cope with the growing proportion of elderly people. Health care systems must be organized effectively, avoiding too many medical interventions, too long hospital stays and inappropriate use of high cost technologies.15, 17 It is important to pay attention at the prevention of chronic diseases. Many risk factors for chronic diseases (e.g. hypercholesterolemia, smoking, overweight) can be prevented by early information, health education and other lifestyle interventions.4, 45, 64 Non-Health Factors Economic burden will increase with the ageing of society. In developed countries, the working part of society, aged between 20 and 60 years old, is getting smaller (see Fig. 1). The maintenance of the social services, in the way they exist in many countries, can give problems. The smaller, working part of the society has to pay relatively more to maintain the welfare state, so there will be a higher economic burden on fewer people.64 Control Strategy There are several problems related to drug development and use in our ageing society. As described above, these problems can be divided into 'individual' problems (e.g. problems with medication) and 'general' problems (e.g. impact of the elderly on the health systems). Individual Problems Clinical trials A main strategy of solving problems with medication in the elderly is to improve the participation of elderly in clinical trials. It is necessary to test new medications in the group who will use those most. Nowadays, people aged 65 and over are often excluded, because of several reasons. The existence of co-morbidity, polypharmacy and the frailty of the elderly make researchers hesitate about the participation of these patients. Next to that, also practical problems like the transport of seniors to research centres can be an obstacle for the inclusion of elderly in clinical trials.4, 45 Despite this, it is really important to include representative samples of elderly into clinical trials which study medications used by elderly. The inclusion of elderly into clinical trials may provide us with important information about dosage, efficacy, long-term effects, dosage regimes and safety of drugs. As described above, in elder people there occur pharmacokinetic and pharmacodynamic changes. This occurs mainly in the very old people, aged 70 and older. So, also very old people need to participate in trials in order to obtain important knowledge about the effects of drugs.8 Comprehensive Monitoring of the Drug Use Process in the Elderly A relative great part of the problems in drug prescription in the elderly is due to the lack of oversight on all therapies a patient is involved with. Many patients are treated by multiple physicians, who are specialized in single 'organ medicine'. To avoid problems it is necessary 7.2-13 Chapter 7.2: Cross-Cutting Issues: Elderly that physicians see and treat a patient as a whole, thereby linking problems and trying by multidisciplinary consultations with the different physicians and pharmacists involved in the treatment of the elderly, to improve the treatment of a patient.45 One way of coping with this problem is to organise multidisciplinary team assessments. All medical professionals involved in a patient's treatment (e.g. physicians and pharmacists) adjust their therapy to each other. In this way, the optimal therapy a patients needs, will be obtained. 53 Advanced information technology (IT) (e.g. individual electronic patient dossiers, EPD) is a resource to address this problem. But successful comprehensive monitoring requires more than introducing new technologies. A systems approach is needed to implement the best mixture of medical, managerial, technological and behavioural strategies.4, 65 General Problems At national and at international level, attention must be paid to the access of elderly to health care. Cost-containment in health care is a major concern in virtually all societies.15 Independent of whatever social, political or economic system exists, governments, insurers and other decision makers struggle with the ever-increasing demand for health care. To cope with the ageing part of society, it is increasingly recognised that the governments need to revise their health systems. Economic experts tell us that there is no way out of a dramatic transformation of our health care systems: they should be organized more effectively, avoiding unnecessary medical interventions and inappropriate use of high cost technologies, and putting more the interest of the elderly patient first instead of letting bureaucrats or technologies drive development.4, 64 It is very important to insure access to health care for the elderly. With a good health system, thereby providing possibilities of quality care to all people, it is possible to prevent the increase of disorders and provide early intervention for diseases.45 European Union: 5th Framework Program13 The European Union is promoting all different types of research by Framework Programs (FP). The 5th Framework Program (1999-2002) pays much attention to the issues related to the ageing society in the Key Action 6: The ageing population and their disabilities. A wide range of issues considering the ageing society were included and €190.1 million of funding had been divided between different research projects. The aim of the 5th FP is to improve the knowledge of the process of ageing and the age-related disorders, and to lighten the burden on the public health systems. The 5th FP, Key Action 6, includes research in all parts of the ageing process, ranging from the underlying cellular and molecular mechanisms of ageing, to the age-related disorders (pathophysiology of Alzheimer's or Parkinson's disease). Also the epidemiological trends and the impact of the ageing society on the health services are studied. How effective is it, or could it be? Reducing Adverse Drug Reactions (ADRs) 7.2-14 Chapter 7.2: Cross-Cutting Issues: Elderly As stated above, many ADRs occur due to several reasons. The percentage of hospital admissions due to adverse drug reactions varied from 0.2% to 41.3%.55 Several studies show that the incidence of fatal adverse drug reactions in hospital patients ranges between 0.2 and 0.7%.6, 7, 54 Next to this, these studies also show that the more serious adverse effects are more likely to be preventable. Two studies by Gurwitz et al show that the percentage of preventable, life-threatening ADRs ranges between 42.2 and 72%, whereas the percentage of significant ADRs which are judged to be preventable, ranges between 18.7 and 34%. 6, 7 These percentages are shocking and are coupled with high rates of morbidity and mortality. Adverse drug reactions induce also an unnecessary loss of health especially in the elderly. As stated before, elderly persons recover less easily from illnesses than younger people do and by preventing hospital admissions, morbidity and mortality will be largely reduced. Stimulating Appropriate Prescribing and Drug Use By stimulating appropriate prescribing by physicians, preventing underuse, guarantee access to health care for all patients and development of adapted formulations for the elderly, optimal treatment will be achieved and the health of the older patient will be sustained. 45, 66 A significant reduction of adverse drug reactions could be achieved by enhancing streamlining of and continuity in the drug use process and better application of modern information technologies like electronic patient dossier (EPD).67 It is well recognised that the introduction of information technology implies a considerable financial investment, but is also expected to give major health returns and even financial profits in the long term. 67 Electronic records can alert and thereby prevent medication errors, resulting in a better prescribing, less adverse drug reactions and fewer unnecessary laboratory costs.67 Why Does the Disease Burden Persist? Because of an increase in socio-economic and environmental conditions, expanded knowledge of the human body and medical care, more people are getting older than ever. The ageing of the society will bring several problems. They cannot be prevented yet, but there are possibilities to cope with the problems, which come along with the growing proportion of elderly in society. Exclusion of the Elderly from Clinical Trials Many of the problems are caused by the historical exclusion of special groups (e.g. children, women, elderly) from clinical trials because of ethical objections and practical problems. Because of the exclusion, there is little knowledge of the process of ageing, the physical changes in elderly people and difficulties, which can occur in case of re-occurrence of diseases or using large amounts of different medications at the same time.3, 4 This seems to be very contradictory, because the people aged 60 and over are using large amounts of medicines and they are the largest growing proportion of the population. So, for pharmaceutical industry the elderly should be an attractive group to develop new medicines for. One of the problems of the participation of elderly in clinical trials is the large amount of drugs the elder people are using. This can occur in higher rates of adverse effects or even in a higher co-morbidity.3 It is understandable that the pharmaceutical industries prefer to 7.2-15 Chapter 7.2: Cross-Cutting Issues: Elderly exclude the group of seniors that are difficult to study. In addition to the problem of the drug-drug interactions there is the problem of higher rates of re-occurrence of disease in the elderly. Different diseases can interfere which each other and with medications; the effects are unknown. In order to avoid a high noise to signal level, people who have different diseases (often elder people) are excluded.4 In the last decade, the proportion of elderly involved in clinical trials is increasing. This is partly due to the development of governmental guidelines, which require the inclusion of special groups into clinical trials (not only elderly68 but also children69 and women70-72). In spite of this, it is important to realise that the elderly who are participating in clinical trials, often are younger and fitter than the general population of older adults.4 Adverse Drug Reactions The higher rate of adverse drug reactions in the elderly causes a higher amount of hospital admissions.55 Because of the increased frailty of the elder people, hospital admissions can more easily result in disability among the elderly in comparison with the younger. The higher incidence of ADRs in the elderly has different reasons. One of the important reasons is inappropriate prescribing of medications by physicians. The inappropriate prescribing is caused by a lack of knowledge of physicians about the pathophysiology and pharmacology of disorders and medicines.61 One other explanation for the higher rate of adverse drug reactions is the use of a large number of medications by seniors, without a good survey of all medications (including OTC-medications) a patient is using.42 Survey of Therapies Several physicians, due to the re-occurrence of different diseases, treat many elderly patients and do not have an accurate survey of the large amounts of drugs the elderly take. In many countries, there is no accurate overview of all (drug) therapies a patient gets. This is estimated to result in medication errors (e.g. due to interactions or dose errors), which can be prevented by an accurate overview of the therapies. Unequal Access to Health Care45 In many countries, retired seniors do not have fixed incomes. When there are little or no social services, it is very difficult for those people to make ends meet every month. Due to this unequal access to health care, many seniors decide not to use all medications prescribed. In the short term, this allows considerable savings for the patient. Over the longer term, costs for health care will be much higher. For example, a person who is not taking his prescribed lipid-lowering statins, saves a considerable amount of money every month. At the same time, his cholesterol is increasing to dangerous values and two years later, he gets a heart attack and needs to be admitted in hospital for at least one week. The hospital admission costs a lot more than a daily statin therapy. Past/Current Research into Pharmaceutical Interventions Stimulating Participation of Elderly in Clinical Research In 1993, EMEA developed a Note for Guidance on the participation of elderly in clinical trials. This Note did not contain obligations, only recommendations are made. 68 Despite this 7.2-16 Chapter 7.2: Cross-Cutting Issues: Elderly guidance, there were several studies published which showed that a large number of clinical trials tend to use unjustifiable age limits.73, 74 It is seen that despite the guidance of EMEA68 the participation of elderly (especially the elderly aged > 75 years old) almost did not increase.73, 74 Therefore, it may be helpful to insert obligations in this guidance, just like the Best Pharmaceuticals for Children Act (BPCA) did in the U.S.A. (2002).75 The exclusion of participation into clinical trials is not a problem specifically for the elderly. It is also a problem in other vulnerable groups, like children and women. The participation of children and women in clinical trials is also negligible, caused by the same reasons as in the elderly. These reasons include practical problems e.g. different pharmacokinetic, and dynamic properties and large differences between age groups in children.76 In children and women in the reproductive age, also ethical considerations play an important role in the decision of the exclusion of clinical research.77 Therefore, off-label and unlicensed drug use is not an acceptable situation in these groups. In order to stimulate the pharmaceutical industries to perform research also in children, in the U.S.A. the Best Pharmaceuticals For Children Act was passed. Next to the obligations this law contains, there is also an prolonged market exclusivity of 6 months for industries who get a license for paediatric use.76 In the European Union, EMEA provided guidelines to improve the paediatric labelling. These guidelines do not include obligations but only recommendations.78 The guidelines and laws recently developed for research in children and women are a good example of the laws and guidelines necessary for research in the elderly. Policy makers should learn from the experience of the current policy in the participation of women and children in research and improve the participation of the elderly in clinical trials by including obligations in the guidelines. Current "Pipeline" of Products Prevention and Management of Adverse Drug Reactions and Medication Errors There are several ways to detect and prevent adverse drug reactions. In the past, voluntary reporting was often used.59 Nowadays, there is much attention to electronic medical records, which point out adverse drug reactions and medication errors, thereby reducing disabilities and saving considerable amounts of money.58, 59 It is seen that the number of computerdetected adverse reactions is much higher than the voluntary reported ADRs. Despite these promising features, the electronic medical record is yet not widely used.79 Opportunities for Research into New Pharmaceutical Interventions There is still a lack of basic knowledge about the process of ageing. Little is known about the origins of changes in pharmacokinetics and -dynamics, the changes in body composition, deterioration of structure and function of organs.8 In order to understand the ageing process and to develop medications that can reverse or halt the ageing process, it is necessary to produce knowledge of the underlying basic principles. Next to that, the development of 7.2-17 Chapter 7.2: Cross-Cutting Issues: Elderly medications for diseases, which occur more common in the elderly, is of significant interest. With the ageing of society, the prevalence of several diseases will increase. Nowadays, many companies are doing research in these areas and the need for suitable medication will increase in the future.80 In patients with dementia, not only medication for prevention, reversion or stopping the disease is needed. There is also a great need for medication that treats the symptoms of these disorders, because there is hardly any treatment available. Patients with dementia often have behavioural disorders, (for example they may behave aggressively), which are very tedious for the patient and his relatives and caregivers. Another important area of research is that of formulations for the elderly. Formulations, which are suitable for middle-aged people, are not automatically suitable for the elderly. More attention must be paid to the development of formulations which are suitable for the elderly, thereby improving adherence.10, 45 What are the gaps between current research and potential research issues which could make a difference are affordable and could be carried out in a) 5 years or b) in the longer term? For which of these gaps are there opportunities for pharmaceutical research? The pharmaceutical industry is doing much research on specific diseases for the elderly (Alzheimer’s disease, Parkinson’s disease and others). All big pharmaceutical companies are doing research in these areas, and have potential drugs in their pipelines.80 For national governments and international institutions like the European Union, it seems not to be a logical step to support this type of research. The big pharmaceutical companies are spending such an enormous amount of money on research; it will not be possible for governmental organisations to accomplish a break-through by the investment of limited public money. The basic research of the principles of the ageing process can be supported by governments. There is still a lack of knowledge of the underlying mechanisms whereas an accurate understanding of these principles would made it easier to understand the pathophysiology of diseases, which occur specific among the elderly. This basic research could occur in the state-subsidized universities. Within the universities there is knowledge and with financial support of the governments, they can do much work in disentangling the process of ageing. Another area, which needs financial support on short term, is the research about the best way to organise the health systems. With the ageing of population, the demands of the health systems increase in a comparable way. To ensure the access to health care for all people, it is really necessary to study on the best way to organise the health systems.15 There are other areas in which great efforts are needed to improve the health care for elderly. Clinical Trials 7.2-18 Chapter 7.2: Cross-Cutting Issues: Elderly As discussed in this paper, the exclusion of the elderly in clinical trials leads to a lack of knowledge on the use of drugs in elderly.3, 81 There is little information about issues like doses, administration regimes and adverse drug reactions.45 This may lead to inaccurate treatment of elder patients, resulting in increasing morbidity and higher costs.4 By improving the participation of elderly in clinical trials, these problems might be solved. Despite the guidance of EMEA (1995),68 elderly are still excluded from clinical trials, mainly for unjustifiable reasons.73 By developing laws and guidelines which include obligations towards the participation of the elderly, government could improve the knowledge of drug effects in the elderly, thereby providing more accurate health care and preventing medication errors.4 To improve the participation of the elderly in clinical trials, a cooperation between pharmaceutical industry and governments is warranted.45 Together it is possible to develop guidelines and recommendations to carry out clinical research in elderly in an ethical way, with sufficient numbers of elderly patients participating and with practical problems to be solved more easily.81 Drug Formulations After marketing of a new drug, changes in doses are often seen. 82 As discussed before, these changes are often due to altered body functions in the elderly.3, 8 Because of the lack of knowledge about the drug effects in elderly, these adaptations are mainly educated guesses.4 Appropriate dosing is the key to successful drug development and dosing in the elderly is an Achilles' heel of drug innovation. Next to adapted doses for the elderly, special formulations might be required. Due to physical or cognitive impairment, problems (e.g. difficulties with opening medication containers, too large pills to swallow or problems with reading drug monographs) might occur. By developing special formulations for the elderly, adherence can be improved and taking medications will be a less discomforting experience. Monitoring of Safety of Drug Use in the Elderly Adverse drug reactions and medication errors occur frequently in the elderly. 83, 84 Most of these events are preventable.6, 7 Therefore by providing a system which can monitor all therapies a patient is involved with, adverse drug reactions and other medication errors might be prevented.67 This may result in reduced hospital admissions, increasing quality of life and considerable savings.57 The introduction of these monitoring systems comes with considerable costs.67 With governmental support, either by financial support or by practical support, it may be easier for health services to introduce advanced monitoring systems.85 Appropriate Prescribing By stimulating appropriate prescribing by physicians underuse but also polypharmacy might be prevented. Thereby the optimal therapy for the patient can be obtained.42, 61 A significant reduction of adverse drug reactions could be achieved by improving drug prescribing, thereby reducing costs and increasing quality of life.4, 42 7.2-19 Chapter 7.2: Cross-Cutting Issues: Elderly Access to Health Care Many elderly can not afford the health care they need. This may lead to a sub optimal use of health care.45 For example blood pressure in patients with hypertension is only controlled adequately in a minority of the elder patients. This is partly due to a poor access to health care in the elderly.45 This unequal access to health care may therefore lead to less benefit of existing therapies, which may lead to increasing morbidity and increasing costs.4 Conclusion The number of elderly is increasing dramatically in virtually all regions in the world. The ageing society comes along with several specific problems.2 The frailty of the elderly, the increasing prevalence of diseases (including co-morbidities) and the large numbers of drugs used per patient have a major impact on the health systems. 3, 4 Therefore patient safety, a key public health issue particularly in this population, should be at the top of our menu. In the last decade, the awareness of the impact of the growing numbers of elderly has increased. The ageing society has been one of the Key Actions of the 5th Framework Program of the European Union. Within this program, much attention is paid to effective and efficient delivery of health and social care services to elder people.13 Despite the efforts made by the 5th FP, it is important to improve the knowledge of the basic principles of the ageing process. Beside that, it is important to gain knowledge about the drug effects in the elderly. Therefore it is necessary to include them in clinical trials. There is a special need for guidelines which stimulate the inclusion of the people aged 70 and older in clinical trials.4 References 1. 2. 3. 4. 5. 6. 7. 8. World Population Prospects: The 2002 Revision, Highlights. New York: United Nations Population Division; 2003. Report No.: ESA/P/WP. 180. http://www.un.org/esa/population/unpop.htm. Department of Economic and Social Affairs Population Division. Population database. Last accessed May 15, 2004 Crome P. What's different about older people. Toxicology 2003;192(1):49-54. Simon SR, Gurwitz JH. Drug therapy in the elderly: improving quality and access. Clin Pharmacol Ther 2003;73(5):387-393. Thomas EJ, Brennan TA. Incidence and types of preventable adverse events in elderly patients: population based review of medical records. BMJ 2000;320(7237):741-744. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and Preventability of Adverse Drug Events Among Older Persons in the Ambulatory Setting. JAMA 2003;289(9):1107-1116. Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, Eckler M, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000;109(2):87-94. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004;57(1):6-14. 7.2-20 Chapter 7.2: Cross-Cutting Issues: Elderly 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. Hanlon J, Schmader K, Ruby C, Weinberger M. Suboptimal prescribing in older patients and outpatients. J Am Geriatr Soc 2001;49(2):200-209. Rodenhuis N BD, de Smet PAGM. Patient experiences with the performance of tablet score lines needed for dosing. Pharm World Sci 2003;25(4):173-176. Nikolaus T, Kruse W, Back M. Elderly patients problems with medication. Eur J Clin Pharmacol 1996;49(4):255-259. Thwaites J. Practical aspects ofdrug treatment in elderly patients with mobility problems. Drug Aging 1999;14(2):105-114. 5th Framework Program, Key Action 6: Age-related problems and disability. Brussels: European Union; 2003. Califf RM. Benefit the patient, manage the risk: a system goal. Pharmacoepidemiol Drug Saf 2004;13(5):269-276. Szucs TD. Future Disease Burden in the Elderly: Rationale for Economic Planning. Cardiovasc Drugs Ther 2001;15:359–361. Edwards LD. Drug research in older patients. In: Fletcher AJ, Edwards LD, Fox AW, Stonier P, editors. Principles and Practice of Pharmaceutical Medicine. Chichester, UK: John Wiley & Sons, Ltd.; 2002. Active Ageing: A Policy Framework. Geneva: World Health Organisation; 2002. Report No.: WHO/NMH/NPH/02.8. Morley JE. The Top 10 Hot Topics in Aging. J Gerontol A Biol Sci Med Sci 2004;59(1):M24-33. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet neurology 2003;2(1):43-53. Aronow WS, Ahn C, Gutstein H. Prevalence and Incidence of Cardiovascular Disease in 1160 Older Men and 2464 Older Women in a Long-term Health Care Facility. J Gerontol A Biol Sci Med Sci 2002;57(1):M45-46. Investigators CIS, Rengo F, Acanfora D, Trojano L, Furgi G, Picone C, et al. Congestive heart failure in the elderly. Arch Gerontol Geriatr 1996;23(3):201-223. Bouvy M, Heerdink E, Leufkens H, Hoes A. Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. Eur J Heart Fail 2003;5(2):195-200. Rich MW. Management of Heart Failure in the Elderly. Heart Fail Rev 2002;7(1):89-97. Ritchie K, Lovestone S. The dementias. Lancet 2002;360(9347):1759-1766. Kukull WA, Ganguli M. Epidemiology of dementia: concepts and overview. Neurol Clin 2000;18(4):923-950. Hofman A, Rocca WA, Brayne C, Breteler MM, Clarke M, Cooper B, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol 1991;20(3):736-748. Samuelsson AM, Annerstedt L, Elmsa S. Burden of responsibility experienced by family caregivers of elderly dementia sufferers. Scand J Caring Sci 2001;15(1):25-33. Wancata J, Musalek M, Alexandrowicz R, Krautgartner M. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur Psychiatry 2003;18(6):306-313. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18(1):19-31. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62(1):10-15. Friedman JH, Fernandez HH, Trieschmann MM. Parkinsonism in a nursing home: underrecognition. J Geriatr Psychiatry Neurol 2004;17(1):39-41. 7.2-21 Chapter 7.2: Cross-Cutting Issues: Elderly 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. Lundback B, Gulsvik A, Albers M, Bakke P, Ronmark E, van den Boom G, et al. Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly. Eur Respir J Suppl 2003;40:3s-9s. Calverley PMA, Walker P. Chronic obstructive pulmonary disease. Lancet (North American edition) 2003;362(9389):1053-1062. Menotti A, Mulder I, Nissinen A, Giampaoli S, Feskens EJM, Kromhout D. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year allcause mortality: The FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol 2001;54(7):680-686. Kjoller E, Kober L, Iversen K, Torp-Pedersen C, Trace Study Group obot. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. Eur J Heart Fail 2004;6(1):71-77. Heikkinen R-L, Kauppinen M. Depressive symptoms in late life: a 10-year follow-up. Arch Gerontol Geriatr 2004;38(3):239-250. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999;60 Suppl 20:9-15. Woolf AD, Pfleger B. Burden of musculoskelatel disorders. Policy and Practice. Special Theme-Bone and Joint Decade 2000-2010. Bull World Health Organ 2003;81(9):646-656. Leveille SG. Musculoskeletal aging. Curr Opin Rheumatol 2004;16(2):114-118. Laiho K, Tuomilehto J, Tilvis R. Prevalence of rheumatoid arthritis and musculoskeletal diseases in the elderly population. Rheumatol Int 2001;20(3):85-87. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton IL, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004;19(6):893-899. Jackson SH, Mangoni AA, Batty GM. Optimization of drug prescribing. Br J Clin Pharmacol 2004;57(3):231-236. Stewart RB, Cooper JW. Polypharmacy in the aged. Practical solutions. Drugs Aging 1994;4(6):449-461. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent Patterns of Medication Use in the Ambulatory Adult Population of the United States: The Slone Survey. JAMA 2002;287(3):337-344. Murray MD, Callahan CM. Improving Medication Use for Older Adults: An Integrated Research Agenda. Ann Intern Med 2003;139(5_Part_2):425-429. Aronson JK. In defence of polypharmacy. Br J Clin Pharmacol 2004;57(2):119-120. Wald N, Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326(7404):1419-1425. Hanlon J, Schmader K, Boult C, Artz M, Gross C, Fillenbaum C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002;50(1):26-34. Hanlon J, Artz M, Pieper C, Lindblad C, Sloane R, Ruby C, et al. Inappropriate medication use among frail elderly impatients. Ann Pharmacother 2004;38(1):9-14. Onder G, Landi F, Cesari M, Gambassi G, Carbonin P, Bernabei R. Inappropriate medication use among hospitalized older adults in Italy: results from the Italian Group of Pharmacoepidemiology in the Elderly. Eur J Clin Pharmacol 2003;59(2):157-162. Lipton H, Bero L, Bird J, McPhee S. The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing. A randomized controlled trial. Med Care 1992;30(7):646-658. Schmader K, Hanlon J, Weinberger M, Landsman P, Samsa G, Lewis I, et al. Appropriateness of medication prescribing in ambulatory elderly patients. J Am Geriatr Soc 1994;42(12):12411247. Routledge P, O'Mahony M, Woodhouse K. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2004;57(2):121-125. 7.2-22 Chapter 7.2: Cross-Cutting Issues: Elderly 54. 55. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200-1205. Beijer HJM, Blaey CJd. Hospitalisations caused by adverse drug reactions (ADR): a metaanalysis of observational studies. Pharm World Sci 2002;24(2):46-54. 56. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998;45(3):301-308. Lagnaoui R, Moore N, Fach J, Longy-Boursier M, Begaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000;56(2):181-186. Hope C, Overhage JM, Seger A, Teal E, Mills V, Fiskio J, et al. A tiered approach is more cost effective than traditional pharmacist-based review for classifying computer-detected signals as adverse drug events. J Biomed Inform 2003;36(1-2):92-98. Gandhi T, Seder D, Bates D. Methodology matters. Identifying drug safety issues: from research to practice. Int J Qual Health Care 2000;12(1):69-76. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002;162(20):2269-2276. Aronson JK. Rational prescribing, appropriate prescribing. Br J Clin Pharmacol 2004;57(3):229230. McGraw C, Drennan V. Self-administration of medicine and older people. Nurs Stand 2001;15(18):33-36. Eijken Mv, Tsang S, Wensing M. Interventions to improve medication compliance in older patients living in the community: a systemic review of literature. Drugs Aging 2003;20(3):229240. program Aalc. Active Ageing: A Policy Framework. Geneva: World Health Organization; 2002. Report No.: WHO/NMH/NPH/02.8. Nebeker JR, Hurdle JF, Bair BD. Future History: Medical Informatics in Geriatrics. J Gerontol A Biol Sci Med Sci 2003;58(9):M820-825. Zhan C, Sangl J, Bierman AS, Miller MR, Friedman B, Wickizer SW, et al. Potentially Inappropriate Medication Use in the Community-Dwelling Elderly: Findings From the 1996 Medical Expenditure Panel Survey. JAMA 2001;286(22):2823-2829. Wang SJ, Middleton B, Prosser LA, Bardon CG, Spurr CD, Carchidi PJ, et al. A cost-benefit analysis of electronic medical records in primary care. Am J Med 2003;114(5):397-403. Note for guidance on studies of support special populations: geriatrics. London: EMEA; 1995. Report No.: CPMP/ICH/379/95. www.emea.eu.int/htms/human/peg/peg.htm. EMEA. The European Paediatric Intiative (PEG). Last accessed 14 September, 2004 General considerations for clinical trials. London: The European Agency for the Evaluation of Medicinal Products (EMEA); 1997. Report No.: CPMP/ICH/291/95. Guidance for Industry: Establising Pregnancy Exposure Registries: FDA: U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER); 2002 August 2002. Note for guidance on the exposure to medicinal products during pregnancy: Need for postauthorization data. London: European Medicines Agency; 2004. Bayer A, Tadd W. Unjustified exclusion of elderly people from studies submitted to research ethics committee for approval: descriptive study. BMJ 2000;321(7267):992-993. Bugeja G, Kumar A, Banerjee AK. Exclusion of elderly people from clinical research: a descriptive study of published reports. BMJ 1997;315(7115):1059. 't Jong GW. Unlicensed and off-label drug use in children [PhD Thesis]. Rotterdam: Erasmus University Rotterdam; 2002. Jong GWt. Unlicensed and off-label drug use in children. Rotterdam: Erasmus University Rotterdam; 2002. 7.2-23 Chapter 7.2: Cross-Cutting Issues: Elderly 77. 78. 80. 81. 82. 83. 84. 85. Steinbrook R. Testing Medications in Children. N Engl J Med 2002;347(18):1462-1470. Ceci A, Felisi M, Catapano M, Baiardi P, Cipollina L, Ravera S, et al. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products. Eur J Clin Pharmacol 2002;58(8):495-500. 79. Murff HJ, Patel VL, Hripcsak G, Bates DW. Detecting adverse events for patient safety research: a review of current methodologies. J Biomed Inform 2003;36(1-2):131-143. http://www.phrma.org/newmedicines. Pharmaceutical Research and Manufacturers of America. New Medicines in Development. Last accessed June 6, 2004 Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials. N Engl J Med 1999;341(27):2061-2067. Heerdink ER, Urquhart J, Leufkens HG. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf 2002;11(6):447-453. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-Drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity. JAMA 2003;289(13):1652-1658. Hanlon JT, Lindblad CI, Hajjar ER, McCarthy TC. Update on drug-related problems in the elderly. Am J Ger Pharmacother 2003;1(1):38-43. Adams T, Budden M, Hoare C, Sanderson H. Lessons from the central Hampshire electronic health record pilot project: issues of data protection and consent. Br Med J 2004;328(7444):871874. 7.2-24